Three Unmet Needs Defining HS Treatment
What the FSGS Market Shift Means for Commercial Strategy
After decades with no approved therapy, the FSGS treatment landscape is changing within a compressed window. Travere’s Filspari (sparsentan) is newly approved by the FDA as of April 13, 2026, [...]
Systemic Lupus Erythematosus (SLE): A Market in Transition
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder marked by unpredictable organ involvement, clinical variability, and a high burden of chronic therapy. For biopharma teams evaluating opportunity in SLE, [...]
Why IgA Nephropathy Is Entering a New Commercial Phase
What evolving risk definitions, shifting treatment expectations, and B cell immunomodulation mean for drug developers IgA nephropathy (IgAN) is no longer a niche renal indication defined by slow progress and [...]
Filspari and Tarpeyo launches off to a great start in IgAN (MARKETVUE® REPORT)
Surveyed nephrologists by REACH Market Research report that Filspari and Tarpeyo are already being prescribed to as many as 1 in 5 IgAN patients. NEWTON, Mass., July 27, 2023 /PRNewswire/ -- IgA nephropathy (IgAN) is [...]
~20% of Dupixent-treated atopic dermatitis patients are refractory to the drug (MARKETVUE® REPORT)
While non-response to Dupixent is uncommon, atopic dermatitis (AD) patients who are refractory lack safe and effective treatments. NEWTON, Mass., July 26, 2023 /PRNewswire/ -- Atopic dermatitis (AD) is a chronic, inflammatory [...]
Less than half of endocrinologists are impressed with Tzield’s ability to delay T1D (MARKETVUE® REPORT)
Sanofi/formerly Provention's Tzield (teplizumab), a CD3 mAb, is the only FDA-approved disease-modifying therapy that delays progression of Stage 2 T1D in patients 8 years and older. However, less than half [...]
There is significant need for efficacious membranous nephropathy treatments for high-risk patients (MARKETVUE® REPORT)
Nearly 1 in 5 membranous nephropathy patients never achieve remission, and nearly one-third of those that do will relapse. NEWTON, Mass., May 24, 2023 /PRNewswire/ -- Membranous nephropathy (MN) is a rare, [...]
Spevigo launch going well for Generalized Pustular Psoriasis (MARKETVUE® REPORT)
Boehringer-Ingelheim's intravenous Spevigo (spesolimab) is a therapy specifically indicated to treat active Generalized Pustular Psoriasis (GPP) flares. Nearly 90% of dermatologists with prior use reported spesolimab as very effective, according [...]